Dual agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-10. Anything still debated is marked as such rather than presented as settled.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Like Truman and Eisenhower, John F. Kennedy supported containment. President Eisenhower's New Look policy had emphasized the use of less expensive nuclear weapons to deter Soviet aggression by threatening massive nuclear attacks on all of the Soviet Union. Nuclear weapons were much cheaper than maintaining a large standing army, so Eisenhower cut conventional forces to save money. Kennedy implemented a new strategy known as flexible response. This strategy relied on conventional arms to achieve limited goals. As part of this policy, Kennedy expanded the United States special operations forces, elite military units that could fight unconventionally in various conflicts. Kennedy hoped that the flexible response strategy would allow the US to counter Soviet influence without resorting to nuclear war. To support his new strategy, Kennedy ordered a massive increase in defense spending and a rapid build-up of the nuclear arsenal to restore the lost superiority over the Soviet Union. In his inaugural address, Kennedy promised "to bear any burden" in the defense of liberty, and he repeatedly asked for increases in military spending and authorization of new weapons systems. From 1961 to 1964, the number of nuclear weapons increased by 50 percent, as did the number of B-52 bombers to deliver them. The new ICBM force grew from 63 intercontinental ballistic missiles to 424. He authorized 23 new Polaris submarines, each of which carried 16 nuclear missiles. Kennedy also called on cities to construct fallout shelters.
=== Sweden === The Swedish Armed Forces use ration packs from the Swedish-developed 24 hour meals. 24 hour meals have a long range of menus (approx. 200) and can deliver both freezedried and wet meals. The Swedish concept (combat edition) consists of several versions for different use, in all climate zones, and various types of missions. Examples of different types of rations: 1-course (patrolration), 2-course, 3-course and 4-course versions with a variation of 40 different meals, both wet and dry. The rations varies from 1300 kcal to 5000 kcal. The ration is packed in a transparent durable plastic bag that is resealable with a ziplock. The contents are 1–4 main meals with energy bars, protein bars, nuts, energy drinks, whole wheat bread, peanut butter, desserts and spices for example. The durable bag change size depending on the version for optimal space usage in cartons and soldiers' backpacks. 24 hour meals have been developed at a rapid pace and are currently producing their 5th generation (first in 2008). R&D are working close with soldiers in Scandinavia and various missions around the world.
=== Filtration === The Celle engineer, Wilhelm Berkefeld, recognized the ability of diatomaceous earth to filter and developed tubular filters (known as filter candles) fired from diatomaceous earth. During the cholera epidemic in Hamburg in 1892, these Berkefeld filters were used successfully. One form of diatomaceous earth is used as a filter medium, especially for swimming pools. It has a high porosity because it is composed of microscopically small, hollow particles. Diatomaceous earth (sometimes referred to by trademarked brand names such as Celite) is used in chemistry as a filtration aid, to increase flow rate, and filter very fine particles that would otherwise pass through or clog filter paper. It is also used to filter water, particularly in the drinking water treatment process and in fish tanks, and other liquids, such as beer and wine. It can also filter syrups, sugar, and honey without removing or altering their color, taste, or nutritional properties.
It is localized in the cytosol, but in response to high glucose it becomes glycosylated by OGT and/or phosphorylated by ERK, which causes translocation to the nucleus. In the nucleus β2 heterodimerizes with E47, binds to the E1 element of the insulin promoter and recruits co-activator p300 which acetylates β2. It is able to interact with other transcription factors as well in activation of the insulin gene. MafA is degraded by proteasomes upon low blood glucose levels. Increased levels of glucose make an unknown protein glycosylated. This protein works as a transcription factor for MafA in an unknown manner and MafA is transported out of the cell. MafA is then translocated back into the nucleus where it binds the C1 element of the insulin promoter. These transcription factors work synergistically and in a complex arrangement. Increased blood glucose can after a while destroy the binding capacities of these proteins, and therefore reduce the amount of insulin secreted, causing diabetes. The decreased binding activities can be mediated by glucose induced oxidative stress and antioxidants are said to prevent the decreased insulin secretion in glucotoxic pancreatic β cells. Stress signalling molecules and reactive oxygen species inhibits the insulin gene by interfering with the cofactors binding the transcription factors and the transcription factors itself. Several regulatory sequences in the promoter region of the human insulin gene bind to transcription factors.
If this occurs and the user takes a dose comparable to their previous use, the user may experience drug effects that are much greater than expected, potentially resulting in an overdose. It has been speculated that an unknown portion of heroin-related deaths are the result of an overdose or allergic reaction to quinine, which may sometimes be used as a cutting agent.
Sources: en.wikipedia.org
=== Research profile and funding === Arizona is classified among "R1: Doctoral Universities – Very high research activity". The University of Arizona achieved $1.012 billion in research expenditures for fiscal year 2024, ranking 19th among public universities nationwide. The University of Arizona is the fourth most awarded public university by NASA for research. UA students have been selected as Truman, Rhodes, Goldwater, and Fulbright Scholars. According to The Chronicle of Higher Education, UA is among the top 25 producers of Fulbright awards in the U.S. UA is a member of the Association of Universities for Research in Astronomy, a consortium of institutions pursuing research in astronomy. The association operates observatories and telescopes, notably Kitt Peak National Observatory just outside Tucson. UA is a member of the Association of American Universities.
Norgestrienone, also known as 17α-ethynyl-19-nor-δ9,11-testosterone or as 17α-ethynylestra-4,9,11-trien-17β-ol-3-one, as well as δ9,11-norethisterone or 17α-ethynyltrienolone (17α-ethynyltrenbolone), is a synthetic estrane steroid and a derivative of testosterone and 19-nortestosterone. It is structurally related to the anabolic steroid trenbolone (19-nor-δ9,11-testosterone; the non-17α-ethynylated analogue of norgestrienone), the progestogenic and androgenic steroid gestrinone (the 13β-ethyl variant or 18-methyl derivative of norgestrienone), and the anabolic steroid tetrahydrogestrinone (the 18-methyl and 17α-ethyl variant of norgestrienone).
==== Women's international friendly matches ==== 22 February – China 0–0 Ireland. 8 April – USA 2–0 Ireland. 11 April – USA 1–0 Ireland. 22 June – Ireland 3–2 Zambia. 6 July – Ireland 0–3 France. 14 July – A friendly pre-World Cup warmup match against Colombia in Brisbane was abandoned after 20 minutes following harsh incidents by the South Americans against Denise O'Sullivan and Ruesha Littlejohn which earned the offenders yellow cards. O'Sullivan went to hospital with an injury inflicted by Colombian Daniela Caracas who said after the match that the Irish players "are little girls" ("Son unas nenas"), and "let them eat shit" ("que coman mierda").
== External links == European Union Observatory for Nanomaterials (EUON) Acquisition, evaluation and public orientated presentation of societal relevant data and findings for nanomaterials (DaNa) Safety of Manufactured Nanomaterials: OECD Environment Directorate Assessing health risks of nanomaterials summary by GreenFacts of the European Commission SCENIHR assessment Textiles Nanotechnology Laboratory at Cornell University Nano Structured Material Online course MSE 376-Nanomaterials by Mark C. Hersam (2006) Nanomaterials: Quantum Dots, Nanowires and Nanotubes online presentation by Dr Sands Lecture Videos for the Second International Symposium on the Risk Assessment of Manufactured Nanomaterials, NEDO 2012 Nader Engheta: Wave interaction with metamaterials, SPIE Newsroom 2016 Managing nanomaterials in the Workplace by the European Agency for Safety and Health at Work.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.